pSivida Corp. (PSDV) Sees Large Volume Increase
pSivida Corp. (NASDAQ:PSDV) saw strong trading volume on Tuesday . 57,574 shares traded hands during trading, a decline of 7% from the previous session’s volume of 61,814 shares.The stock last traded at $3.49 and had previously closed at $3.47.
Separately, FBR & Co reiterated a “buy” rating on shares of pSivida Corp. in a research report on Wednesday, August 10th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $7.00.
The firm’s market cap is $118.42 million. The company has a 50 day moving average of $3.86 and a 200-day moving average of $3.28.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/psivida-corp-psdv-sees-large-volume-increase.html
pSivida Corp. (NASDAQ:PSDV) last announced its quarterly earnings data on Monday, September 12th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.13) by $0.06. pSivida Corp. had a negative return on equity of 106.84% and a negative net margin of 1,330.06%. Equities research analysts anticipate that pSivida Corp. will post ($0.69) earnings per share for the current fiscal year.
A number of institutional investors have recently made changes to their positions in PSDV. BlackRock Fund Advisors boosted its position in shares of pSivida Corp. by 10.7% in the second quarter. BlackRock Fund Advisors now owns 82,473 shares of the company’s stock valued at $233,000 after buying an additional 7,956 shares during the period. Acadian Asset Management LLC boosted its position in shares of pSivida Corp. by 62.0% in the first quarter. Acadian Asset Management LLC now owns 140,869 shares of the company’s stock valued at $377,000 after buying an additional 53,892 shares during the period. Geode Capital Management LLC boosted its position in shares of pSivida Corp. by 18.1% in the first quarter. Geode Capital Management LLC now owns 141,663 shares of the company’s stock valued at $379,000 after buying an additional 21,720 shares during the period. Opus Point Partners Management LLC purchased a new position in shares of pSivida Corp. during the first quarter valued at about $482,000. Finally, Sabby Management LLC boosted its position in shares of pSivida Corp. by 85,693.3% in the first quarter. Sabby Management LLC now owns 293,585 shares of the company’s stock valued at $787,000 after buying an additional 293,928 shares during the period. Hedge funds and other institutional investors own 30.09% of the company’s stock.
pSivida Corp. Company Profile
pSivida Corp. is a biotechnology company, which is engaged in the development of sustained-release drug-delivery products for treating eye diseases. The Company offers products for treatment of back-of-the-eye diseases. The Company’s lead development product, Medidur is used for posterior of the eye (posterior uveitis).
Receive News & Ratings for pSivida Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for pSivida Corp. and related companies with MarketBeat.com's FREE daily email newsletter.